Literature DB >> 19117052

Altered gene expression in breast cancer liver metastases.

Nuray Erin1, Ning Wang, Ping Xin, Voung Bui, Judith Weisz, Guliz A Barkan, Wei Zhao, Debra Shearer, Gary A Clawson.   

Abstract

We previously developed a highly aggressive cell line from heart metastases of 4T1 breast carcinoma (designated 4THM), which produced liver metastases (designated 4TLM). In this study, gene array analysis (GAEA) compared gene expression profiles in 4TLM with profiles in 4T1 and 4THM primary tumors. GAEA demonstrated that 4T1 and 4THM tumors differed in about 250 genes. Over 1,000 genes, however, were expressed differently in 4TLM compared with primary tumors. A cohort of 16 genes showed significantly decreased expression in 4THM tumors, which decreased even further in 4TLM. Many of these genes have been implicated in breast cancer, and many are involved in cell adhesion and junctional complexes. Expression of multiple tight and adherence junction proteins was either downregulated or disappeared in 4TLM; downregulation of claudin 4, claudin 7 and gamma-catenin was confirmed by quantitative polymerase chain reaction, immunoblot, and immunocytochemical (ICC) analyses. At the protein level, intact ZO-1 was also observed in 4T1 tumors, but was not expressed in 4THM or 4TLM tumors. ICC demonstrated expression of gamma-catenin at the plasma membrane with 4T1 tumors, whereas staining appeared to be nuclear/perinuclear in 4THM tumors. Claudin 7 staining was also seen in monocyte/pmacrophage-like cells in liver around metastatic lesions by ICC, and it appeared that larger 4TLM tumors apparently reexpressed claudin 7 RNA and protein. Our results demonstrate that decreased or abnormal expression of a number of cell adhesion/junctional proteins, including claudin 4, 7, ZO-1 and gamma-catenin, correlates with liver metastases, and that cell adhesion molecules in the microenvironment are also altered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19117052     DOI: 10.1002/ijc.24131

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Hepatic tight junctions: from viral entry to cancer metastasis.

Authors:  Nikki P Lee; John M Luk
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

2.  Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response.

Authors:  N Erin; A Podnos; G Tanriover; Ö Duymuş; E Cote; I Khatri; R M Gorczynski
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

3.  Nephronectin is Decreased in Metastatic Breast Carcinoma and Related to Metastatic Organs.

Authors:  Sayra Dilmac; Nuray Erin; Necdet Demir; Gamze Tanriover
Journal:  Pathol Oncol Res       Date:  2017-08-25       Impact factor: 3.201

4.  Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.

Authors:  Nagarajan Kannan; Jian Kang; Xiangjun Kong; Jianzhong Tang; Jo K Perry; Kumarasamypet M Mohankumar; Lance D Miller; Edison T Liu; Hichem C Mertani; Tao Zhu; Prudence M Grandison; Dong-Xu Liu; Peter E Lobie
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

5.  Expression of tight junction molecules in breast carcinomas analysed by array PCR and immunohistochemistry.

Authors:  Anna-Mária Tőkés; Attila Marcell Szász; Eva Juhász; Zsuzsa Schaff; László Harsányi; István Arthur Molnár; Zsolt Baranyai; István Besznyák; Attila Zaránd; Ferenc Salamon; Janina Kulka
Journal:  Pathol Oncol Res       Date:  2011-12-23       Impact factor: 3.201

6.  Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

Authors:  Siker Kimbung; Anikó Kovács; Pär-Ola Bendahl; Per Malmström; Mårten Fernö; Thomas Hatschek; Ingrid Hedenfalk
Journal:  Mol Oncol       Date:  2013-10-14       Impact factor: 6.603

Review 7.  Polarity proteins as regulators of cell junction complexes: implications for breast cancer.

Authors:  Dana Bazzoun; Sophie Lelièvre; Rabih Talhouk
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

8.  Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures.

Authors:  Bruce Pulford; Natalia Reim; Aimee Bell; Jessica Veatch; Genevieve Forster; Heather Bender; Crystal Meyerett; Scott Hafeman; Brady Michel; Theodore Johnson; A Christy Wyckoff; Gino Miele; Christian Julius; Jan Kranich; Alan Schenkel; Steven Dow; Mark D Zabel
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

9.  Endostatin enhances radioresponse in breast cancer cells via alteration of substance P levels.

Authors:  Esra Arslan Aydemir; Ece Simsek Oz; Aylin Fidan Korcum; Kayahan Fiskin
Journal:  Oncol Lett       Date:  2011-07-04       Impact factor: 2.967

10.  HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.

Authors:  Şule Kale; Aylin F Korcum; Ertuğrul Dündar; Nuray Erin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-09-14       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.